Drug Trial Radar · NCT00334958
Rufinamide Given as Adjunctive Therapy in Participants With Refractory Partial Seizures
Last checked: Nov 19, 2026Latest source record: Jun 14, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
356
Actual
Start
Feb 13, 2006
Primary completion
May 20, 2009
Study completion May 20, 2009
Sponsor
- Lead sponsor
- Eisai Inc.Eisai
- Sponsor type
- Industry
- First posted
- Jun 8, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the effect of rufinamide on total partial seizure frequency in adolescent and adult participants (12 to 80 years, inclusive) with refractory partial onset seizures maintained on a maximum of 3 stable antiepileptic drugs (AEDs).
Conditions
- Epilepsy
Interventions
PlaceboDrug
For the 12-day Titration Phase, one matching placebo tablet will be administered twice daily and increased by 1 matching placebo tablet every 3 days up to maximum of 4 matching placebo tablets twice daily (placebo tablet matched to rufinamide total daily dose of 3200 mg). For the 12 week maintenance phase, 4 placebo tablets matching to rufinamide maintenance doses of 1600 mg twice daily (3200 mg total daily dose) will be administered. Similar to the dose reduction permitted in the rufinamide group, participants in placebo group will be allowed only during the Titration Phase to have the dose reduced to 3 placebo tablets twice daily.
RufinamideDrug
For the titration phase, Rufinamide will be administered orally in doses starting with 400 mg twice daily and increased every 3 days in 400 mg twice daily increments up to 1600 mg twice daily (total daily dose 3200 mg). For the Maintenance Phase, maintenance doses of 1600 mg twice daily (3200 mg total daily dose) will be administered. Participants unable to tolerate the target dose (3200 mg/day) will be allowed only during the Titration Phase to have the dose reduced to 3 tablets twice daily (corresponding to a dose of 2400 mg/day in the rufinamide group).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage Change in Total Partial Seizure Frequency Per 28 Days During Maintenance Phase Relative to the Baseline PhaseTime frame: Baseline, Days 13 to 96
Locations
77 sites in 1 country. Site status is shown where the registry gives one.
University of South Alabama Medical Center
Mobile, Alabama
Neurology Clinic PC
Northport, Alabama
Barrow Neurological Institute
Phoenix, Arizona
Mayo Clinic Epilepsy and Neurology
Phoenix, Arizona
University of Arizona, Dept. of Neurology
Tucson, Arizona
Clinical Trials, Inc
Little Rock, Arkansas
Neuro-Pain Medical Center, Inc.
Fresno, California
Neurology Center
Oceanside, California
California Pacific Epilepsy
San Francisco, California
Georgetown University Hospital, Dept. of Neurology
Washington D.C., District of Columbia
Children's National Medical Center
Washington D.C., District of Columbia
Bradenton Research Center
Bradenton, Florida
University of Florida, Dept. of Neurology
Gainesville, Florida
University of Florida, The Neuroscience Institute at Shands
Jacksonville, Florida
Pediatric Neurologists of Palm Beach
Loxahatchee Groves, Florida
Nemours Children's Clinic
Orlando, Florida
Pediatric Neurology - PA
Orlando, Florida
Bay Medical Center
Panama City, Florida
University of Southern Florida, Dept. of Neurology
Tampa, Florida
Child Neurology Associates, PC
Atlanta, Georgia
Medical College of Georgia, Dept. of Neurology
Augusta, Georgia
Medical Associates of North Georgia
Canton, Georgia
The Queen's Medical Center
Honolulu, Hawaii
Children's Memorial Hospital, Northwest University
Chicago, Illinois
Advocate Hope Children's Hospital
Oak Lawn, Illinois
Advocate Lutheran General Children's Hospital
Park Ridge, Illinois
Southern Illinois University Neurology and Pharmacology
Springfield, Illinois
Mcfarland Clinic
Ames, Iowa
Via Christi Comprehensive Epilepsy Center
Wichita, Kansas
University of Kentucky, Dept. of Neurology
Lexington, Kentucky
John Hopkins Hospital, Dept. of Neurology
Baltimore, Maryland
Children's Hospital Boston
Boston, Massachusetts
Boston University Medical Center, Dept. of Neurology
Boston, Massachusetts
University of Massachusetts, Neurology Associates
Hopedale, Massachusetts
University of Minnesota, Dept. of Neurology
Minneapolis, Minnesota
Minnesota Epilepsy Group, PC
Saint Paul, Minnesota
Ronald Schwartz, M.D.
Hattiesburg, Mississippi
Hattiesburg Clinic
Hattiesburg, Mississippi
The Comprehensive Epilepsy Care Center for Children and Adults
Chesterfield, Missouri
Saint John's Medical Research
Springfield, Missouri
Showing 40 of 77 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.